New Tilray Medical Study on Medical Cannabis Highlights Reduced Pain and Improved Sleep for Fibromyalgia Patients

Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY) and a leading global player in the medical cannabis sector, recently released a new study, “Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS),”. The company’s mission is to connect patients with the latest scientific research in a more convenient way, aiming to treat illness and deliver tailored health advice and guidance with objective data from Tilray’s growing database of over 3 million anonymous medical records.

This real-world study based on healthcare providers’ experiences assessed the impact of cannabinoid treatments on individuals diagnosed with fibromyalgia (FM). It evaluated the effects of Dried Flower THC18 from Tilray on chronic pain, sleep disorders, and different symptoms potentially linked to FM. The striking results demonstrate how health outcomes can be impacted by cannabinoids, particularly for pain relief, sleep quality, and overall satisfaction.

The findings showed marked progress in pain management, improved sleep quality, and greatly enhanced health overall for fibromyalgia sufferers, with an average age of 52, under the care of qualified medical cannabis specialists. In addition, subjects reduced dependence on other drugs, implying that cannabinoids might represent an effective and inexpensive option for treating this group.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.